All In Biotech

Drug Trial Radar · NCT04756037

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,164

Actual

Start

Mar 18, 2021

Primary completion

Feb 25, 2025

Study completion Mar 31, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.

Conditions

  • Contraception

Interventions

  • Relugolix Combination TherapyDrug

    Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contraceptive Efficacy of Relugolix Combination Therapy as Assessed by the At-Risk Pearl Index (PI)Time frame: 13 consecutive 28-day treatment cycles

Locations

112 sites in 2 countries. Site status is shown where the registry gives one.

  • Mobile

    Mobile, Alabama

  • Chandler

    Chandler, Arizona

  • Mesa

    Mesa, Arizona

  • Peoria

    Peoria, Arizona

  • Phoenix

    Phoenix, Arizona

  • Burbank

    Burbank, California

  • Canoga Park

    Canoga Park, California

  • Encinitas

    Encinitas, California

  • Gardena

    Gardena, California

  • Lancaster

    Lancaster, California

  • Long Beach

    Long Beach, California

  • Long Beach

    Long Beach, California

  • Palo Alto

    Palo Alto, California

  • Sacramento

    Sacramento, California

  • San Diego

    San Diego, California

  • San Fernando

    San Fernando, California

  • Valley Village

    Valley Village, California

  • West Covina

    West Covina, California

  • Aurora

    Aurora, Colorado

  • Greenwood Village

    Greenwood Village, Colorado

  • Washington

    Washington D.C., District of Columbia

  • Washington

    Washington D.C., District of Columbia

  • Aventura

    Aventura, Florida

  • Boynton Beach

    Boynton Beach, Florida

  • Davie

    Davie, Florida

  • Deland

    DeLand, Florida

  • Hialeah

    Hialeah, Florida

  • Jacksonville

    Jacksonville, Florida

  • Kissimmee

    Kissimmee, Florida

  • Lake Worth

    Lake Worth, Florida

  • Loxahatchee

    Loxahatchee Groves, Florida

  • Margate

    Margate, Florida

  • Miami

    Miami, Florida

  • Miami

    Miami, Florida

  • Miami

    Miami, Florida

  • Miami

    Miami, Florida

  • New Port Richey

    New Port Richey, Florida

  • Orlando

    Orlando, Florida

  • Orlando

    Orlando, Florida

  • Panama City

    Panama City, Florida

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.